Background: Invasive aspergillosis (IA) is a severe infection in immunocompromised patients. Recently, serum galactomannan
has been widely used for diagnosis and voriconazole as an antifungal agent. The objective of this study is to describe clinical features and survival outcomes of IA.
Material and Method: A retrospective chart review of IA in patients younger than 18 years old at King Chulalongkorn
Memorial Hospital, Thailand, was conducted. Clinical definitions were based on criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) 2008.
Results: Between January 2006 and December 2012, 40 cases of invasive aspergillosis were identified, classified as proven
(8 patients, 20%), probable (28, 70%), and possible IA (4, 10%). Median age of patients was 10 years (range, 42 days-17
years). The most common underlying disease was hematologic malignancy (60%). The major risk factor was neutropenia (65%) with median duration of 21 days (range, 4-58 days). The most common site of infection was in the lungs (80%). The most common computed tomography chest finding was nodules (71%). An air crescent sign was seen only in 11% and a halo sign was found only in 7% of patients. Serum galactomannan was positive in 78% of patients with median value of 1.34 (range 0.5-5.6). Only seven patients (17%) had microbiological confirmation, of which were Aspergillus flavus (4 cases) and Aspergillus fumigates (3 cases). Antifungal therapy included voriconazole (23 patients, 58%), amphotericin B (12, 30%), liposomal amphotericin B (3, 8%), caspofungin (1, 2%) and itraconazole (1, 2%). Two deaths related to angioinvasive
complications of aspergillosis (pulmonary hemorrhage and rupture mycotic aneurysm) were reported. The 3-month and 12-
month survival rates after diagnosed IA were 73.7% and 56.7%, respectively. The major cause of death was new episode of sepsis found in 11 cases (52%).
Conclusion: The 1-year survival rate was poor; however, cause of death is related to complications of the immunocompromised
state not from IA.

Keywords: Invasive aspergillosis, Antifungal therapy, Treatment outcome